Uncategorized

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Published

4 hours ago

on

Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs.​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version